• Korro Bio outlined value-creation priorities centered on RNA editing therapies that do not permanently modify DNA.
• KRRO-111 named as a development candidate for a GalNAc-conjugated alpha-1 antitrypsin deficiency program.
• Regulatory clearance to start a first-in-human trial for KRRO-121 is targeted for H2 2026.
• A third GalNAc-conjugated liver development candidate is expected in H2 2026.
• Cash, cash equivalents, and marketable securities totaled $137.9 million as of June 30, 2026; runway projected into H2 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.